A big impact, but to completely protect against this parasite, we are not sure if we need one or more than one target, so that really, the complexity of the parasite drives a lot of that. the other consideration is that even though gsk and other partners have worked on this for decades, investment in malaria has only recently really taken malaria has only recently really ta ken off malaria has only recently really taken off and we are really taken off and we are really glad to see that investment, but for a long time, people who worked on malaria vaccines did so without a lot of funding or sup...